A randomized study involving 3 cohorts to evaluate the role of new immunotherapies and allogeneic hematopoietic stem cell transplantation (allo-HSCT) in the first-line treatment of adult patients with acute lymphoblastic leukemia
Adult acute lymphoblastic leukemia (ALL) comprises three main entities: Philadelphia chromosome–positive ALL (Ph+), Philadelphia chromosome–negative B-cell precursor ALL (Ph− BCP-ALL), and T-cell ALL/lymphoblastic lymphoma (T-ALL/LBL), accounting for approximately 25%, 50%, and 25% of cases, respectively. Recent therapeutic advances have led to a reassessment of the role of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in first complete remission, which is now generally reserved for patients at higher risk, mainly those with high and persistent levels of minimal residual disease (MRD).
Nevertheless, 3-year event-free survival (EFS) remains limited to approximately 60–70%, highlighting the need for innovative strategies to improve disease control while reducing treatment-related toxicity. In this setting, the emergence of immunotherapies has profoundly changed the therapeutic landscape of ALL. Several agents have been approved for patients with relapsed or refractory B-cell ALL, including blinatumomab, a CD19-directed bispecific T-cell engager, which has demonstrated the ability to induce deep responses, including MRD negativity.
The GRAALL-2024 study is a prospective, randomized, multicenter, international clinical trial structured into three cohorts corresponding to the main ALL subtypes: Ph− B-ALL, Ph+ B-ALL, and T-ALL/LBL. After a common prephase, eligible patients are assigned to one of these cohorts. The primary objective is to improve outcomes in adults with ALL through the early, frontline introduction of antibody-based therapies, notably blinatumomab in Ph− and Ph+ disease and a targeted immunotherapy approach in T-ALL, while refining the indication for allo- HSCT in first remission.
Eligibility Criteria
Inclusion criteria:
- Newly diagnosed ALL or T-LL according to WHO criteria.
- Immunophenotypic, cytogenetic, and/or molecular testing has been performed, allowing classification into one of the following cohorts: Ph+ ALL, Ph− BCP ALL, or T-ALL/LL.
- No prior treatment, except for corticosteroids and/or intrathecal therapy (pre-phase).
Exclusion criteria:
- Patients who have previously been treated for ALL with systemic chemotherapy, antibody therapy, or a tyrosine kinase inhibitor (TKI).
- Patients with a pre-existing primary tumor that is currently clinically relevant or requires active treatment.
- Pre-existing or current clinically relevant central nervous system disease.
- Patients with a left ventricular ejection fraction (LVEF) < 50% or another clinically significant heart condition.
Hospitals
-
HFR Freiburg - Kantonsspital
-
Les hôpitaux universitaires de Genève
-
Luzerner Kantonsspital AG
-
Universitätsspital Basel